Roche’s Phase III of tominersen in Huntington's disease has been stopped after an independent interim review, but with no new or emerging safety signals reported, analysts presume efficacy was the problem.

The Swiss major has highlighted two high-risk, high-reward neurodegenerative programs that could be transformative for the treatment of Alzheimer's and Huntington's disease.

However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.

Polyneuron, Synerkine, Harmony, EIP Pharma and AITI Life Sciences all raised cash in recent weeks to tackle various conditions involving the nervous system. More recent venture funding deals...